• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受大剂量环磷酰胺、噻替派和顺铂治疗的患者中噻替派及其代谢产物的尿排泄情况。

Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.

作者信息

van Maanen M J, Huitema A D, Rodenhuis S, Beijnen J H

机构信息

Division of Drug Toxicology, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands.

出版信息

Anticancer Drugs. 2001 Jul;12(6):519-24. doi: 10.1097/00001813-200107000-00005.

DOI:10.1097/00001813-200107000-00005
PMID:11459998
Abstract

The urinary excretion of N,N',N"-triethylenethiophosphoramide (thioTEPA), and its metabolites N,N',N"-triethylenephosphoramide (TEPA), N,N'-diethylene,N"-2-chloroethylphosphoramide (monochloroTEPA) and thioTEPA--mercapturate was determined in patients receiving thioTEPA as part of a high-dose combination chemotherapy regimen with cyclophosphamide and carboplatin. The thioTEPA dose was 40 or 60 mg/m(2) in short infusions, twice daily, during 4 days. Urine samples were collected after each voiding on each day of drug administration until 24--48 h after the last thioTEPA infusion. ThioTEPA, TEPA and monochloroTEPA concentrations were determined with gas chromatography and thioTEPA--mercapturate with liquid chromatography--mass spectrometry with direct sample injection. ThioTEPA was present in urine 30 min after infusion and was still excreted 18 h after the last infusion. All metabolites were detected in urine 1 h after infusion. Patients with a creatinine clearance above 140 ml/minl showed higher excretion of TEPA than patients with a creatinine clearance below 140 ml/min (12.8 versus 4.9%, p=0.01). The excretion of monochloroTEPA relative to the excreted amount of TEPA increased at lower pH values of the urine. The excretion of thioTEPA--mercapturate relative to the dose was higher in patients treated with 60 mg/m(2). Excretion of thioTEPA and monochloroTEPA both accounted for only 0.5% of the dose, while TEPA and thioTEPA--mercapturate both accounted for 11.1%.

摘要

在接受硫替派作为环磷酰胺和卡铂高剂量联合化疗方案一部分的患者中,测定了N,N',N''-三乙烯硫代磷酰胺(硫替派)及其代谢产物N,N',N''-三乙烯磷酰胺(替派)、N,N'-二乙烯基,N''-2-氯乙基磷酰胺(单氯替派)和硫替派-巯基尿酸盐的尿排泄情况。硫替派剂量为40或60mg/m²,短时间输注,每日两次,共4天。在给药的每一天每次排尿后收集尿液样本,直至最后一次硫替派输注后24 - 48小时。用气相色谱法测定硫替派、替派和单氯替派的浓度,用直接进样的液相色谱-质谱法测定硫替派-巯基尿酸盐的浓度。输注后30分钟尿液中出现硫替派,最后一次输注后18小时仍有排泄。输注后1小时在尿液中检测到所有代谢产物。肌酐清除率高于140ml/min的患者比肌酐清除率低于140ml/min的患者显示出更高的替派排泄率(12.8%对4.9%,p = 0.01)。尿液pH值较低时,单氯替派相对于替派排泄量的排泄率增加。接受60mg/m²治疗的患者中,硫替派-巯基尿酸盐相对于剂量的排泄率更高。硫替派和单氯替派的排泄量均仅占剂量的0.5%,而替派和硫替派-巯基尿酸盐均占11.1%。

相似文献

1
Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.接受大剂量环磷酰胺、噻替派和顺铂治疗的患者中噻替派及其代谢产物的尿排泄情况。
Anticancer Drugs. 2001 Jul;12(6):519-24. doi: 10.1097/00001813-200107000-00005.
2
Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine.硫替派及其代谢产物替派、一氯替派和硫替派巯基尿酸在血浆和尿液中的稳定性。
Int J Pharm. 2000 May 10;200(2):187-94. doi: 10.1016/s0378-5173(00)00370-7.
3
A search for new metabolites of N,N',N''-triethylenethiophosphoramide.N,N',N''-三乙烯硫代磷酰胺新代谢产物的研究。
Cancer Res. 1999 Sep 15;59(18):4720-4.
4
Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.使用毛细管气相色谱法同时测定尿液中的硫替派、替派以及一种新的、最近鉴定出的硫替派代谢物——一氯替派。
J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):335-43. doi: 10.1016/s0378-4347(00)00181-x.
5
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.噻替派及其代谢产物的人体血浆药代动力学和尿排泄情况。
Cancer Treat Rep. 1986 Jul;70(7):859-64.
6
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.环磷酰胺及其代谢产物4-羟基环磷酰胺、2-去氯乙基环磷酰胺和磷酰胺芥在与噻替派和卡铂高剂量联合使用时的群体药代动力学。
Ther Drug Monit. 2005 Dec;27(6):756-65. doi: 10.1097/01.ftd.0000177224.19294.92.
7
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.环磷酰胺、噻替派和卡铂大剂量化疗中暴露与毒性的关系。
Ann Oncol. 2002 Mar;13(3):374-84. doi: 10.1093/annonc/mdf052.
8
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.阿瑞匹坦抑制环磷酰胺的生物活化和噻替派的代谢。
Cancer Chemother Pharmacol. 2005 Oct;56(4):370-8. doi: 10.1007/s00280-005-1005-4. Epub 2005 Apr 19.
9
Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.一名接受高剂量环磷酰胺、噻替派和卡铂治疗的肥胖患者出现极高暴露量。
Cancer Chemother Pharmacol. 2002 Sep;50(3):251-5. doi: 10.1007/s00280-002-0494-7. Epub 2002 Jul 30.
10
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.环磷酰胺和噻替派在传统分次高剂量方案与新型简化单次方案中的药代动力学比较。
Ther Drug Monit. 2009 Feb;31(1):95-103. doi: 10.1097/FTD.0b013e318194e484.

引用本文的文献

1
Hemophagocytic Syndrome-Associated Intravascular Large B-cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease Treated With Autologous Stem Cell Transplantation Using a Modified TEAM Regimen.采用改良TEAM方案行自体干细胞移植治疗伴透析依赖终末期肾病的噬血细胞综合征相关血管内大B细胞淋巴瘤
Cureus. 2022 Jun 12;14(6):e25885. doi: 10.7759/cureus.25885. eCollection 2022 Jun.
2
A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics.基于 UPLC-ESI-QTOFMS 的代谢组学研究全面了解噻替派在小鼠体内的代谢情况。
Biochem Pharmacol. 2011 Apr 15;81(8):1043-53. doi: 10.1016/j.bcp.2011.01.024. Epub 2011 Feb 12.